Ireland
--:--IST
Starting soon Observational

Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome

NCT07109778 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-08-01
Last updated
2025-08-07

Condition(s) studied

ESRD (End Stage Renal Disease)Control Condition

Study summary

The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * ESRD patients including those on maintenance HD Exclusion Criteria: * Acute kidney injury or rapidly progressive glomerulonephritis, acute infections or active inflammatory conditions as sepsis and autoimmune diseases, liver cirrhosis (Child-Pugh Class B or C), gastrointestinal disorders as inflammatory bowel disease, malabsorption, history of organ transplantation excluding kidney transplantation who may be included in a separate analysis if sufficient numbers are recruited, receiving total parenteral nutrition, Cu or Zn metabolism disorders as Wilson's disease, vitamin complex supplementation or antioxidants within the past 6 months, recent hospitalization within the past 3 months, recent surgery within 3 months, recent blood transfusion \< 3 months, Pregnancy or lactation, Malignancy.

Primary outcome measure(s)

  • To determine whether an elevated serum Cu/Zn ratio is associated with an increased risk of cardiac complications in chronic hemodialysis patients. — 6-8 months
    measuring serum Cu/Zn ratio and determining if it is associated with an increased risk of cardiac complications in chronic hemodialysis patients.

Trial sites (1)

FacilityCityRegionStatus
Nephrology and urology hospital, Minia unersity hospital, Faculty of medicine, Minia university Minya Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07109778 on ClinicalTrials.gov ↗ ← All trials in Egypt